TARA Protara Therapeutics, Inc.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1359931 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY-48.3%
TTM EPS YoY-0.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-57.4%
ROA-52.1%
ROIC (approx.)-57.3%
Asset turnover—
Leverage & solvency
Liabilities / assets9.9%
Debt / equity0.00x
Current ratio9.01x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.92x
Accruals ratio-4.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | — | — | — | — | — |
| R&D expense | $16.80M | $16.95M | $13.56M | $13.12M | $9.59M | $10.77M | $9.15M | $9.50M |
| SG&A expense | $6.35M | $6.37M | $6.07M | $5.96M | $5.17M | $5.82M | $4.98M | $4.81M |
| Operating income | -$23.15M | -$23.32M | -$19.63M | -$19.08M | -$14.76M | -$16.59M | -$14.12M | -$14.31M |
| Net income | -$21.69M | -$21.67M | -$17.78M | -$17.31M | -$13.26M | -$14.96M | -$11.91M | -$12.77M |
| EBITDA | -$23.08M | -$23.25M | -$19.54M | -$18.99M | -$14.67M | -$16.49M | -$14.04M | -$14.23M |
| EPS (basic) | -0.35 | -0.36 | -0.31 | — | -0.31 | -0.35 | -0.29 | — |
| EPS (diluted) | -0.35 | -0.36 | -0.31 | — | -0.31 | -0.35 | -0.29 | — |
| Weighted avg. shares (diluted) | 62.85M | 61.01M | 57.54M | — | 42.27M | 42.27M | 40.71M | — |
| Banking | ||||||||
| Net interest income | $1.29M | $1.48M | — | — | $1.06M | $1.22M | — | — |
| Balance sheet | ||||||||
| Cash & equivalents | $25.15M | $17.08M | $14.74M | $49.66M | $13.30M | $32.24M | $92.21M | $163.54M |
| Short-term investments | $101.90M | $125.42M | $121.05M | $105.90M | $120.12M | $90.72M | $32.90M | $7.49M |
| Current assets | $129.67M | $146.15M | $140.00M | $159.50M | $135.64M | $125.09M | $126.53M | $172.16M |
| PP&E, net | $1.58M | $1.32M | $669,000 | $759,000 | $828,000 | $912,000 | $988,000 | $1.03M |
| Total assets | $156.54M | $176.09M | $191.92M | $209.47M | $144.64M | $156.93M | $168.56M | $181.45M |
| Current liabilities | $14.39M | $13.32M | $8.92M | $10.94M | $9.91M | $9.76M | $7.02M | $10.96M |
| Total liabilities | $15.52M | $14.78M | $10.71M | $13.06M | $12.35M | $12.51M | $10.07M | $14.32M |
| Shareholders' equity | $141.02M | $161.31M | $181.21M | $196.41M | $132.29M | $144.42M | $158.48M | $167.13M |
| Shares outstanding | 59.97M | 59.08M | 55.06M | 53.59M | 38.59M | 38.58M | 38.58M | 35.04M |
| Cash flow statement | ||||||||
| Operating cash flow | -$18.44M | -$15.39M | -$21.34M | -$16.95M | -$12.45M | -$12.25M | -$14.71M | -$9.31M |
| Capital expenditure | $723,000 | — | — | $24,000 | $4,000 | $22,000 | $44,000 | $0 |
| Free cash flow | -$19.16M | — | — | -$16.97M | -$12.46M | -$12.27M | -$14.76M | -$9.31M |
| Investing cash flow | $26.10M | $17.75M | -$14.72M | -$26.91M | -$6.51M | -$47.72M | -$58.35M | $22.50M |
| Financing cash flow | $412,000 | -$26,000 | $1.14M | $80.96M | $13,000 | $8,000 | $1.73M | $97.85M |
| Depreciation & amortization | $71,000 | $72,000 | $90,000 | $93,000 | $88,000 | $98,000 | $83,000 | $82,000 |
| Stock-based compensation | $1.59M | $1.38M | $1.36M | $1.04M | $1.05M | $903,000 | $833,000 | $904,000 |
Free plan shows the latest 8 periods; Pro shows all 55 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.